

INFORMATION & DISCLOSURE STATEMENT
PURSUANT TO RULE 15c2-11
OF THE SECURITIES AND EXCHANGE ACT OF 1934

Current Information Regarding

BIOTECH MEDICS, INC.
Name of Issuer

Corporate Services of Nevada
507 North Division Street
Carson City, NV 89703
Official Nevada Address of Issuer

(972) 274-5533
Telephone Number of Issuer

90-0264349
Federal Employer Identification Number

Dated: June 30, 2008

INFORMATION & DISCLOSURE STATEMENT
PURSUANT TO RULE 15c2-11
OF THE SECURITIES AND EXCHANGE ACT OF 1934

Current Information Regarding

BIOTECH MEDICS, INC.

Name of Issuer

Urban Center-Regis H-Q Offices
222 Las Colinas Blvd., W., Suite 1650 East Tower
Dallas, TX 75039 USA

Official Texas Address of Issuer

(972) 274-5533

Telephone Number of Issuer

(972)-692-5544

Facsimile Number of Issuer

The following information is provided to assist investors and securities brokerage firms with “due diligence” compliance. This statement has not been filed with the Financial Industry Regulatory Authority, a/k/a: FINRA (formerly: NASD) or any other regulatory agency. This information is set forth below as to BIOTECH MEDICS, INC. (referred to as “We” or the “Company”).

The information provided follows the same numbering system found in the rule to wit:

Item 1. Exact Name of Issuer and Predecessor:

Issuer: BioTech Medics, Inc. from November 19, 2004 to Present

Previous Names: Corbel Holdings, Inc. from April 30, 2001 to November 18, 2004

Summit Property Group, Inc. from December 29, 1997 to April 29, 2001

Item 2. Address of Issuer's Principal Executive Offices:

Corporate Services of Nevada
507 North Division Street
Carson City, NV 89703
Telephone No.: (972) 274-5533
Facsimile No.: (972) 692-5441
Website Address: www.biotechmedics.com

Item 3. State and Date of Incorporation:

We were incorporated on December 29, 1997, in the State of Nevada.

Item 4. Exact Title and Class of Security:

We are currently authorized to issue two classes of stock, **common stock** and **preferred stock**. The CUSIP for our common stock is 090699307.

Our common stock has only been quoted on the Pink Sheets on an unsolicited basis since it initiated trading on the Pink Sheets. Our current stock symbol is "BMCS." Pink Sheets has discontinued the display of quotes on pinksheets.com for our common stock from time to time.

Our preferred stock does not have a CUSIP and is not publicly nor privately traded.

Item 5. Par Value or Stated Value of Security:

Our common stock has a par value of \$0.001 per share.

Preferred Stock par value of \$0.001 per share.

Item 6. Number of Shares or Total Amount of the Securities Outstanding As of the End of the Issuer's Most Recent Fiscal Quarter and Fiscal Year and any Offerings of Securities in the Last Two Years:

A. Number of Shares Outstanding

Common Stock

We are authorized to issue Five Hundred Million (500,000,000) shares of common stock, par value \$0.001.

As of 06/30/2008 we had Outstanding Shares (O/S) of **49,045,132¹**

Of the Total Shares Outstanding, **4,957,161** were “free trading float” as of 06/27/08, according to the Depository Trust Corporation (DTCC). Most of the remaining shares are “RESTRICTED” and cannot be traded without a registration statement and/or a legal opinion exempting the shares from registration.

There is an “administrative hold” on 3,000,000 common free trading shares held by a Trustee, In The Matter of the SEC vs. North American Clearing, Inc., US Dist Court, Orlando, FL, Case No. 5:08-CV-829-ORL-31 LLC. Therefore, the DTCC reflected on 06/27/08 7,957,161 shares in their reporting system, but 3,000,000 cannot be traded due to the SEC injunctive relief and Permanent Injunction issued in the US Dist Ct case cited in the previous sentence. These shares will be returned to the Company cancelled and returned to the Company treasury upon release by the Trustee in the matter.

Preferred Stock

We are authorized to issue 10,000,000 shares of preferred stock, par value \$.001, the rights, privileges, and preferences of which may be set by the Board of Directors without further shareholder approval. **However, as of the date of this report, there were no plans to issue Preferred shares in the Company.**

Note: There have been several malicious and false posts on the Raging Bull and other Bulletin Boards by a Cyberbasher who posts anonymously. The Cybersmearer has made hundreds of attempts to disparage the Company by making false statements. One such false statement is that the Company has issued “preferred shares in secret” and caused “massive dilution”. Again, these are malicious and false (untrue) posts made to discourage legitimate retail investing in the stock.

As of the date we provided information in response to this item, no shares of our preferred stock have been issued.

¹ This figure includes shares that are under “administrative hold” as some of the shareholders are being challenged due to the Company audit of the corporate records under prior management (before December 7, 2004, the reverse/merger). The audit has uncovered shares that were stolen, forged and/or illegally issued without consideration and/or a legal opinion that would provide for their exemption to be free trading. There are also shares that are abandoned under the Nevada Unclaimed Property Law NRS 120A.260 as the shares are over 3 years old and under \$50 in value and had no activity.

B. Offerings of Securities

Within the last two year periods ending on the date of our last fiscal year and as of the date of this Disclosure Statement, we have had the following offerings of our securities:

1. In 2005 the Company issued a Minn. Exempt Reg D 504 Private Placement of Common Shares. These were issued prior to a 10 to 1 reverse stock split and a 20 to 1 second reverse stock split.

7. In 2006 the Company issued a Texas Exempt Reg D 504 Private Placement of Common Shares. These were issued prior to a 10 to 1 reverse stock split and a 20 to 1 second reverse stock split.

8. In June, 2007 the Company issued a Texas Exempt Reg D 504 Private Placement of Common Shares. These were issued subsequent to a 10 to 1 reverse stock split and prior to a 20 to 1 second reverse stock split.

Item 7. Name and Address of Transfer Agent:

Transfer Online
317 SW Alder Street, 2nd Floor
Portland OR 97204
Telephone No. (503) 227-2950

Web site: www.transferonline.com

Our transfer agent is registered under the Exchange Act.

Item 8. Nature of the Issuer's Business:

A. Business Development

Summit Property Group, Inc., was organized on December 29, 1997, to operate as a property owner and/or management service. On December 7, 2004, we acquired HaloLaser BioTherapy, LLC, and now focus on alternative health, medicine and medical devices for the twenty-first century. Information concerning the following specific items is furnished to provide a more complete understanding of the issuer's business development:

1. The form of organization of the Issuer;

We are a Nevada corporation.

2. The year that the Issuer (or any predecessor) was organized;

We were incorporated on December 29, 1997, in the State of Nevada, as Summit Property Group, Inc.

3. The Issuer's fiscal year end date;

Our fiscal year end date is December 31.

4. Whether the Issuer (and/or any predecessor) has been in bankruptcy, receivership or any similar proceeding;

We have not been in bankruptcy, receivership or any similar proceeding.

5. Whether the Issuer has made any material reclassification, merger, consolidation, or purchase or sale of a significant amount of assets not in the ordinary course of business;

The Company has reclassified a Promissory Note issued December 17, 2004 by Hamilton Holding PA Corp ("Hamilton") to BioTech Medics, Inc., in the amount of One Million (\$1,000,000.00) dollars. Hamilton has defaulted on the Note and it is the subject of civil litigation in the 68th Texas District Court, Dallas, Texas. The Company upon settlement of the civil case will write the Note off as a loss.

6. Any default of the terms of any note, loan, lease, or other indebtedness or financing arrangement requiring the issuer to make payments;

The Company is in dispute over sums owed American Express and an AT&T invoice. The Company has or is renegotiating several credit card rates and balances from as high as 31% APR, down to 15% APR or lower.

7. Any change of control;

On December 7, 2004, we acquired all of the outstanding membership interests of HaloLaser BioTherapy, LLC in exchange for 66% of the common stock. The entire prior board of directors resigned and the Company came under new management and a new board of directors.

8. Any increase in 10% or more of the same class of outstanding equity securities;

Not subsequent to the previously reported December 7, 2004, acquisition in Section 7 above. At the time this did not constitute an increase greater than 10% of outstanding equity securities. Through the issuance of 504 stock in 2005 and 2006, this did constitute a greater than 10% increase or more of the same class of outstanding equity securities.

9. Describe any past, pending or anticipated stock split, stock dividend, recapitalization, merger, acquisition, spin-off or reorganization;

There were two (2) prior reverse stock splits in 2007. The first took place in the second quarter of 2007 and was a ten for one (10 for 1) reverse stock split. The second took place in the fourth quarter of 2007. It was a twenty to one (20 to 1) reverse stock split.

The reverse stock splits were due to irregularities found in the audit of previous Corbel Holdings shares and shareholders. The Company in conducting an audit of the shareholders uncovered that there had been nearly 50 million common shares illegally issued, stolen and/or forged certificates and/or common shares placed into the retail market place without the prerequisite legal opinion releasing any restrictions on the shares or qualifying exemption from registration of those shares. This alleged criminal activity has caused the Company not to be able to become a Reporting Company until the SEC and other regulatory agencies bring charges against those involved. Under the Sarbanes-Oxley Act, the CEO of the Company must certify under oath and penalties of perjury that the shareholder list complies with all regulations. At this time, this cannot be done until the SEC and other regulatory agencies bring civil and criminal charges against those who allegedly have broken the law and their shares are deleted from the shareholder list. Note: neither the Company, nor any of the current officers and/or directors have had anything to do with the prior previous management and ownership irregularities. Also, the Company has not been informed that it is the subject of any investigation. The Company officers have been noticed by the SEC that they may be used as victim/witnesses for the SEC in their complaints against those who have allegedly committed civil and criminal violations.

The two reverse splits effectively reduced the holdings of those nearly 50 million common shares illegally issued, stolen, forged and/or placed into the retail market place to 250,000 shares.

Since March, 2005, the Board of Directors on behalf of the shareholders of the Company have filed over 36,000 pages of evidence with various regulatory agencies including but not limited to the Securities & Exchange Commission-Enforcement Divisions, Fort Worth, Texas, Los Angeles, CA and Washington, DC, FINCEN, FINRA (formerly NASD) Washington, DC, the Texas Securities Commission, the Nevada Attorney General, the U.S. Treasury Dept., the U.S. Dept of Justice, the Florida Banking Commission with formal complaints regarding the nearly 50 million shares in question. Each member of the board has given sworn testimony and/or had personal conversations with members of the SEC Enforcement Division.

As a result of the Company's filing of various formal complaints the Securities and Exchange Commission brought a civil complaint in April, 2008 in the U.S. District Court, Las Vegas, NV Case No. 2:08-cv-00437-LRH-RJJ, captioned SEC vs. CMKM Diamond, Inc., URBAN CASAVANT, JOHN EDWARDS, GINGER GUTIERREZ, AMES KINNEY, ANTHONY TOMASSO, KATHLEEN TOMASSO, 1ST GLOBAL STOCK TRANSFER LLC, HELEN BAGLEY, NEVWEST SECURITIES CORPORATION, DARYL ANDERSON, SERGEY RUMYANTSEV, ANTHONY SANTOS, and BRIAN DVORAK. The CMKM shareholders directly involved in BMCS are John Edwards, Anthony Tomasso, Kathleen Tomasso. Additional third parties are 1st

Global Stock Transfer, LLC, Helen Bagley, Nevwest Securities, Sergey Rumyantsev and Anthony Santos. The SEC has indicated that there will additional charges brought before the end of the year.

NOTE: The Company BioTech Medics, Inc., is **NOT** under any known investigation by any local, state or federal regulatory agency. Keith Houser has been designated as a “victim/witness” by a federal agency and most likely will testify in any pending civil and criminal proceedings.

We may make new acquisitions, and we may be unable to successfully integrate those acquisitions with our business, impairing our financial performance. If appropriate opportunities present themselves, we may acquire businesses, products or technologies that we believe are strategic. If we do succeed in acquiring a business, product or technology, we have limited experience in integrating an acquisition into our business. The process of integration may produce unforeseen operating difficulties and expenditures and may absorb significant attention of our management that would otherwise be available for the ongoing development of our business, which may harm our business, financial condition or results of operations.

Acquisitions:

On December 17, 2004, the Company acquired all of the common stock of Charles R. Crane MD & Associates, Inc., for 1,250,000 common shares and a promissory note for \$1.25 million.

On March 18, 2005, the Company acquired the four (4) US Letters of Patent from FHJ Scientific for 1,250,000 common shares and a promissory note for \$1.25 million.

On July 19, 2007, the Company acquired the interests in BioBody Products with 5,000,000 common restricted 144 shares.

10. Any delisting of the Issuer’s securities by any securities exchange or NASDAQ or deletion from the OTC Bulletin Board;

Our securities have not been de-listed by any securities exchange or NASDAQ or deleted from the OTC Bulletin Board.

11. Any current, past, pending or threatened legal proceedings or administrative actions either by or against the Issuer that could have a material effect on the Issuer’s business, financial condition, or operations. Any current, past or pending trading suspensions by a securities regulator.

The Company is in litigation with Adam Barnett, an individual of Miami, Florida in a Texas 68th Dist Ct, civil case. The Company legal counsel has issued an opinion that this is a frivolous lawsuit which should have no adverse material effect on the Company. The case is scheduled to be dismissed on Nov. 10, 2008.

B. Business of Issuer

We, (1) sell one or more types of FDA 510(k) cleared medical laser devices for the treatment of numerous symptoms and physical ailments of the human body associated with pain; we (2) train and certify medical professionals in the use of our laser devices; we (3) manage; market and affiliate with pain management and wellness medical centers in the United States; (4) acquired US letters of patent and proprietary SHBAN Solution products and/or devices that compliment our goals of offering alternative medicine for the twenty-first century; and (5) sell BioBody Products™ containing liquid vitamins and minerals and other known ingredients beneficial to the body.

Information concerning the following specific items is provided to the extent material to an understanding of the issuer:

1. Issuer's primary and secondary SIC Codes;

Primary: 8090 (Health & Allied Services)
Secondary: 62134 (Physical, Occupational Therapy)
Other: 62111 (Offices of Physician)
62151 (Medical & Diagnostic Labs)

2. If the Issuer has never conducted operations, is in the development stage or is currently conducting operations;

We are currently conducting operations.

3. State the names of any parent, subsidiary, or affiliate of the issuer, and describe its business purpose, its method of operation, its ownership, and whether it is included in the financial statements attached to this disclosure document;

The Company issues a combined financial statement with the income and expenses of the Charles R. Crane MD & Associates, Inc., a/d/b/a BioTech Laser Centers of TX, LLC (a Pain Management & Wellness Clinic) in Dallas, Texas and BioBody Products.

4. Effect of existing or probable governmental regulations on the business;

Failure to comply with local state and federal governmental requirements could adversely affect our business. On a federal level the **FDA, EPA, FTC, OSHA** and other government agencies have stringent rules with respect to the maintenance of specific levels of care of the use of medical laser equipment. Any of these agencies could have a material adverse effect on our business.

Procedures and requirements of the **Patriot Act of 2001, as amended** may expose us to significant costs or penalties.

As participants in the health services industry, our company may be subject to laws and regulations, including the Patriot Act of 2001, that require that we know our customers.

As a public company we must monitor trading of our stock transactions for suspicious financial activities. The cost of complying with the Patriot Act and related laws and regulations is unknown. We face the risk that our policies, procedures, technology and personnel directed toward complying with the Patriot Act are insufficient and that we could be subject to significant criminal and civil penalties due to noncompliance. Such penalties could have a material adverse effect on our business, financial condition and operating results. As a distributor with potential customers worldwide, we may face particular difficulties in identifying our customers and monitoring their compliance with the Patriot Act.

As a public company we are subject to the Securities Act of 1934, as amended and regulations under the Securities & Exchange Commission (SEC). We must monitor trading of our stock transactions for suspicious financial activities (SARS).

As a public company we are subject to state securities statutes.

We are subject to federal and state Equal Opportunity Employment (**EEOC**) rules and regulations.

Each affiliated pain management center is subject to **Health Insurance Portability and Accountability Act (HIPAA)**. The Act included provisions for health insurance portability, fraud and abuse control, tax related provisions, group health plan requirements, revenue offset provisions, and administrative simplification requirements. Additionally the Act creates national standards to protect individuals' medical records and other personal health information.

5. An estimate of the amount spent during each of the last two fiscal years on research and development activities, and, if applicable, the extent to which the cost of such activities are borne directly by customers;

\$25,000 in new Research & Development has been spent during each of the last two fiscal years. The cost will be amortized over 5 years. Previously over \$1 million has been spent on R&D of SHBAN Solution. Regarding the NeuroLase some of the cost of the R&D is included in the cost of equipment sold. Nearly \$35,000 has been spent on BioBody Products in the past 4 years combined.

6. Costs and effects of compliance with environmental laws (federal, state and local);

The Company is required to comply with the Food & Drug Administration (FDA) and the Environmental Protection Agency (EPA) in the operation of medical lasers. The cost of compliance is less than \$2,000 per year per laser. The medical lasers are declared "non-hazardous" by the FDA, therefore, environmental compliance is minimal and should not adversely impact the Company.

7. Number of total employees and number of full time employees.

We have a total of 8 employees, 4 of which are full time employees. Three of the employees are officers of the company.

C. Investment Policies

The officers and directors of the Company buy stock in the Company on a random basis in small amounts of from 200 to 400 shares. During the first two and one half years since the reverse merger in December 7, 2004, the officers and directors did not sell shares in the company, but did acquire shares in the Company. Efforts are made so that shares may not be bought or sold during the first or last 30 minutes of each trading day, thus avoiding any impropriety of allegedly “painting the tape” on the price of the stock.

Item 9. Nature of Products and Services Offered:

1. Principal products or services, and their markets;

The aging of Americans & Europeans has placed a demand upon physicians and other medical practitioners to be able to provide a quick, safe means of treating pain in patients without unnecessary surgery or drugs. World War II Baby boomers are affluent enough to pay for any successful means of treating their weekend inflicted tennis or golf elbow, lower back pain, or other sprains so that they can quickly feel relief and be back to work the same day.

The use of lasers from the mid-1990's through today to correct poor eyesight have demonstrated that people are willing to privately pay for better health, so long as the treatment is quick, safe and effective. Now through the BioTech L³aser™ therapy protocols a large population of over 150 million Americans who are in pain daily (according to the CDC) can be treated effectively at the BioTech Pain Management & Wellness Centers.

BioTech Medics, Inc., believes that a significant opportunity exists with Pain Management & Wellness Centers to effectively address the market need with proprietary medical laser equipment & several alternative means of treatment from conventional competitive pain clinics.

The NeuroLase™ 150 Medical Laser is an FDA 510(k) authorized medical laser. It is one of the most powerful Class III B deep penetration medical lasers in the United States. The Company has developed BioTech L³aser™'s proprietary protocols for 90 pain related ailments that can be safely and effectively used in conjunction with the NeuroLase. NeuroLase holds 2 granted US Letters of Patent protecting the frequency spectrum and high wattage with the capabilities necessary to work the laser's healing effect to reduce or eliminate pain through biological stimulation over any area of the body.

The BioTech Pain Management & Wellness Centers will combine the proprietary BioTech L³aser medical laser protocols, NeuroLase™ medical device, blood testing,

nutrition education with BioBody Products and lifestyle change programs to provide immediate aid to those in acute and chronic pain and help patients regain strength and well-being.

2. Distribution methods of the products or services;

The NeuroLase Medical Laser Device may only be sold to licensed medical practitioners (i.e. medical doctors, chiropractors, osteopaths, podiatrists and dentists). In some states an acupuncturist may be sold a laser.

The Company is negotiating with a premiere franchise consulting company to take the BioTech L3aser Pain Management Center operations national with franchises in all 50 states and overseas.

3. Status of any publicly announced new products or services;

The Company is currently operating or affiliating with pain management centers in Dallas, Texas, Kansas City (Overland Park), Kansas, Albuquerque and Santa Fe, New Mexico. Additional affiliated centers are being negotiated on a regular basis.

4. Competitive business conditions, the issuer's competitive position in the industry, and methods of competition;

There are no known active US companies that have high powered Class III B laser devices similar to the NeuroLase with the patented broad frequency range between 660nm and 1200nm and proprietary 12 watt high power (12,000 mW) afforded the Company as a distributor

Ten or more known US and foreign companies have sought FDA 510(k) marketing authorization for their laser therapy devices such as: Microlight, Erchonia, Thor, Quantum, Dynatronics and Laser Therapeutics. Avicenna has a CLASS IV laser that has strict FDA and OSHA use requirements. All have been granted FDA 510(k) clearance for specified marketing, but eight of the ten operate at 50% to 90% less power.

The other companies do not have the more powerful lasers because they do not have the US patents necessary to have the prerequisite penetrating power and light spectrum for the laser as does the NeuroLase to work quickly, successfully and properly on human muscle and tissue.

There are over 37 known worldwide laser manufacturers that produce flashlight size or small battery pack lasers that sell within a range of \$ 750 to \$29,995. Many low powered lasers are utilized on animals by veterinarians and have been upgraded for human use. The few desktop flashlight lasers designed for physicians range in price from \$1,500 to \$24,999. They operate at one-tenth to one-half the power of the NeuroLase.

Consequently, to accomplish what the NeuroLase™ does in 5 to 20 minutes over one-quarter of a human body would take a competitor's laser over eight hours and numerous visits to the doctor's office.

Our future success depends in part on our ability to develop and enhance our products and services. The healthcare services industry is characterized by rapid technological change and the emergence of new industry standards and practices that could render our existing technology and systems obsolete. There are significant technical and financial risks in the development of new or enhanced products and services,-. These include the risk that we will be unable to effectively use new technologies or adapt our services to emerging industry standards, or develop, introduce and market enhanced or new products and services.

The Company is disparaged by Cybersmearers on various financial bulletin boards.

Quote by Thomas J. Donovan, B.A., Harvard University, magna cum laude, 1975; J.D., University of Pennsylvania, 1978:

"Many public company discussion boards sink into a routine of rumors and recriminations. Occasionally, some of these rumors are serious enough to affect the stock price. The poster may be attempting to take advantage of these stock swings on the basis of his or her trading position. Beyond the short term effect on stock prices, some postings may accuse management of assorted misdeeds or criminal acts. They may disparage the business or products of the company."

An important message from Keith Houser, CEO of BioTech Medics:

We believe it appropriate to pass information on to our site visitors regarding Cybersmearers or "bashers". This company has been the victim of Cybersmearers on a few "message boards". The Company is taking appropriate action to legally counter any false and/or misleading posts. This may include posting on the same message boards information that exposes the Cybersmearers and the malicious deliberate libel, personal and business disparagement. This statement is full disclosure that an officer and/or director of this company is fully authorized to counter-attack Cybersmearers.

Here is proof of what attorney Donovan has stated are acts by bashers:

04 Jan 2005, 11:02 AM Post: "JUST SHORTED THIS PUPPY"

Above the public bulletin board notice is posted that a basher is shorting BTMD stock.

04 Jan 2005, 01:01 PM Post: Has BTMD trading been halted? Hmmmmmmmm

Above we have another basher post a disparaging FALSE statement hoping the stock will fall to fill the short and make a profit for the basher (or bashers) who are shorting.

Thank God the basher's tactics did not work this day, the stock went up, not down.

UPDATE: NEW BASHING AND SHORTING OF BTMD STOCK 01/26/2005:
26 Jan 2005, 12:19 PM EST POST: "SHORT THIS POOCH"

If you happen to come across one of these Cybersmearers, please email us at: cybercriminals@biotechmedics.com Try to copy the details or give us the web site. If you have a question regarding a Cybersmear comment, you are welcome to call or email us for the truth.

*How Cybersmearers Amplify Their Message ***

The perpetrators of Cybersmear (or what is referred to as Internet Terrorism), are prone to predictable patterns. Most common among these is the strategy of amplifying a complaint or several accusations in an attempt to lend credibility. This is done largely through what we call "proliferation and amplification."

The goal of an Internet Terrorist is to inflict harm on the target company or individual. This is done through what must seem to be credible information that also must appear to be large and prevalent.

Here are the consistent tactics of Cybersmearers on-line:

- *Anonymous postings on scattered "chat rooms" and/or bulletin boards.*
- *Look for postings chronicling the "injustices" of the accused company in what appears to be detailed "bashing" or techno-discussion. Look for (amateur, unlicensed) interpretation and conclusions.*
- *Look for information or quotes taken out of context from the accused, or represented in very small segments as to be presented in a more misleading manner.*
- *With very few exceptions these basher will claim a concern for "innocent victims" or the "unsuspecting customer".*
- *With few exceptions these bashers will claim a "neutral" stance, but will solicit either comments or emails which will predominate in the direction of the Smear (this is key to identifying a smear. True neutral discussions open to the public generally occur with both positive and negative viewpoints equally represented. If the balance is tilted too far in one direction, it is the fingerprint of a smear, and the posted comments can safely be considered false).*
- *It is common for all of the comments to be anonymously posted by the perpetrator(s) to create the sense of "unified outrage" or "a virtual stampede of individuals who agree" or "surprising public outrage" (all actual quotes).*
- *Further, perpetrators will anonymously post slightly varying opinions (all in the direction of the smear, of course), so a "discussion" can occur on finer points of the smear, all the while creating the impression of a larger complaint field.*
- *Among what is usually a small circle of smear perpetrators (generally ten or less individuals behind the largest and most famous smears), automatic posting notifications are sent out whenever one individual places new content on the Internet. This allows the others to rush to the scene with their anonymous postings, again, providing amplification*

and a false impression of the scope of the complaint.

- *The band of smear perpetrators will carefully interlink their sites (to a controlled result, over linking is punished by search engines) so that their websites receive high ranking in search result pages.*

- *The smearer's strategy is to accomplish the following in the mind of the reader: "I didn't realize all of this about (company or person). I wouldn't normally believe it, but there is so much of it on the Internet. If it's that prevalent, it must have some truth to it."*

Cybersmear perpetrators have simply followed the historical basis of telling lies successfully and applied it to the Internet.

Adolph Hitler said, "The longer you tell a lie, the more people will believe it."

Our Cybersmear enemies know this strategy well, and they will use the above tactics of "amplification and proliferation" to achieve it.

*** Portions of this information were contributed by*

http://cybersmear.typepad.com/cybersmear_blog/2004/08/how_cybersmeare.html

5. Sources and availability of raw materials and the names of principal suppliers;

The Company is a distributor for the NeuroLase 150C Medical Laser Device manufactured by Spectrum Laser in Colorado Springs, CO. There are ample lasers available at any given time so that the Company may sell them.

System failures or delays may occur in the future and could cause, among other things, unanticipated disruptions in service to our customers, slower system response time resulting in transactions not being processed as quickly as our customers desire, decreased levels of customer service and customer satisfaction and harm to our reputation.

If any of these events were to occur, we could suffer:

- a loss of customers or a reduction in the growth of our customer base;
- increased operating expenses;
- financial losses;
- litigation or other customer claims; and
- regulatory sanctions or additional regulatory burdens.

The Company has acquired the SHBAN™ US Letters of Patent. SHBAN is an antimicrobial solution. The raw materials are readily available from several US and overseas suppliers.

Our inability to protect our intellectual property rights or our infringement of the intellectual property rights of others could adversely affect our business. Laws and our contractual terms may not be sufficient to protect our technology from use or theft by third parties. For instance, a third party might try to reverse engineer or otherwise obtain

and use our technology without our permission and without our knowledge, allowing competitors to duplicate our products. We may have legal or contractual rights that we could assert against such illegal use, but lawsuits claiming infringement or misappropriation are complex and expensive, and the outcome would not be certain.

We may choose not to enforce or protect our intellectual property rights, depending on our strategic evaluation and judgment regarding the best use of our intellectual property portfolio and the recourse available to us.

Patents of third parties may have an important bearing on our ability to offer certain of our BioBody products and services. Our major competitors as well as other companies and individuals may obtain and may have obtained patents related to the technologies for trading the types of products and providing the services we offer or plan to offer. We cannot assure you that we are or will be aware of all patents containing claims that may pose a risk of infringement by our products and services.

In addition, some patent applications in the United States are confidential until a patent is issued and, therefore, we cannot evaluate the extent to which technology concerning our products and services may be covered or asserted to be covered by claims contained in pending patent applications. In general, if one or more of our products or services is found by a court to infringe patents held by others, we may be required to stop developing or marketing the products or services, to obtain licenses to develop and market the services from the holders of the patents or to redesign the products or services in such a way as to avoid infringing those patents. An adverse ruling arising out of any intellectual property dispute could also subject us to significant liability for damages.

6. Dependence on one or a few major customers;

We do not depend on one or a few major customers. However, we may fail to attract customers in a cost-effective manner and our profitability and growth may be impaired. Our profitability and growth will depend on establishing a greater customer base in a cost-effective manner.

Although we plan to spend financial resources on advertising and related expenses, there are no assurances that these efforts will succeed in attracting customers. The financial resources that we allocate to attracting customers may be inadequate. In addition, we believe that rates for desirable advertising and marketing placements are likely to increase in the foreseeable future, and we may be disadvantaged relative to our larger competitors in our ability to expand or maintain our advertising and marketing commitments. Additionally, Internet filter software programs that limit or prevent our world wide web (www) advertisements and other communications from being displayed on or delivered to our current and potential customers' computers are becoming increasingly available.

7. Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including their duration;

The distribution agreement with Spectrum Laser is for three (3) years and renewable. The relationship between Spectrum and the Company is on very good terms.

The BioTech L3aser protocols were originated by Dr. Crane and Keith Houser and they retain a royalty on the protocols.

The Company has no labor contracts.

8. The need for any government approval of principal products or services. Discuss the status of any requested government approvals.

After a lengthy 10 year research and development period with the NeuroLase Medical Device the FDA granted a 510(k) marketing clearance in November, 2003. Clinical Medical studies are currently being conducted utilizing the NeuroLase. No adverse rulings are expected by the FDA which would negatively impact the Company.

Changes in legislation or regulations may affect our ability to conduct our business or reduce our profitability. The regulatory environment in which we operate may change. These changes may affect our ability to conduct our business or reduce our profitability. Our activities may be affected not only by legislation or regulations of general applicability, but also by industry-specific legislation or regulations. The SEC, FDA, EPA, OSHA other U.S. or foreign governmental authorities may adopt new or revised regulations which affect our business. Changes in the interpretation or enforcement of existing laws and rules by those entities may also affect our business.

Item 10. Nature and Extent of Issuer's Facilities:

The Company maintains its Nevada legal corporate offices at Corporate Services of Nevada, 507 North Division Street, Carson City, NV 89703

BMCS's Texas corporate headquarters is located at 222 West Las Colinas Boulevard, Suite 1650 East Tower, Irving, TX 75039. We entered into a lease agreement dated December 7, 2004 to lease the office space for our Texas corporate headquarters for a term of One (1) year, renewable annually.

The Company also has a lease with Boxer Properties and 9535 Forest Lane LLC and rent Suite 240, Dallas, TX 75234 for the BioTech Medics Pain Management & Wellness Center with Dr. Charles R. Crane. The lease ends on October 31, 2008.

We do not own any real estate property or properties for which the book value amounts to 10 percent or more of the total assets of the Company and its consolidated subsidiaries for the last fiscal year.

Item 11. Name of the Chief Executive Officer, Members of the Board of Directors, as well as Counsel, Accountant and Public Relations Consultant:

A. Officers, Directors and Advisors

1. Management

Our directors and officers are as follows:

Name Title

Keith A. Houser Chairman of the Board and Chief Executive Officer

Charles R. Crane President and Director

Kim Peralta Jacobs Secretary/Treasurer and Director

James C. Nairne, Chief Financial Officer

Keith A. Houser has been our Chairman of the Board and Chief Executive Officer since December 7, 2004. In 2001, Mr. Houser founded in 2001 and became president of through 2004, NutriHealth Marketing, subsequently known as HaloLaser BioTherapy, LLC (“Halo”), which became the initial primary distributor for the NeuroLase Medical Laser Device and merged with BioTech Medics in December 2004. Mr. Houser has an extensive marketing background in radio and television broadcasting from 1966 through 2000. He has managed, owned and/or operated radio and television stations from Phoenix, AZ to New York City.

Charles R. Crane has been our President and Director since December 7, 2004. Over the past thirty years, Dr Crane has operated a private medical practice, specializing in Physical Medicine & Rehabilitation and Electromyography. In addition, he is currently a medical consultant for ReviewMed, Shorman Solutions, Austin & Associates and Forte. He is not currently a member of any other board of directors.

Kim Peralta Jacobs has been our Secretary/Treasurer and Director since December 7, 2004. Over the past ten years, Dr. Jacobs has operated a private chiropractic practice in Overland Park, Kansas. She is not currently a member of any other board of directors.

2. General Partners;

BioTech Medics, Inc., is a general partner in BioTech Laser Centers of TX, LLC.

3. Investment Banker;

None.

4. Promoters;

PMR and Associates, San Diego, CA.

5. Control Persons;

Please see the above Management disclosure as well as the following “Beneficial Owners” below for Keith A. Houser, Charles R. Crane and Kim Peralta-Jacobs.

If we lose the services of any of our key personnel, including our chief executive officer, our business may suffer. Our success is heavily dependent on the performance of our executive officers and managers, especially Keith Houser, our Chief Executive Officer.

Our growth and future success will depend, in large part, on the continued contributions of these and other key individuals as well as our ability to motivate and retain these personnel. Loss of any of our key personnel could result in severe hardship in our ability to perform our business plan. We believe that our future success will depend in part on our ability to recruit and retain highly skilled management, sales and marketing and technical personnel. Competition in recruiting personnel in the biotech healthcare technology industry is intense. To accomplish this, we believe that we must provide personnel with a competitive compensation package, including stock options, which will be dilutive to the stockholders.

6. Legal Counsel;

Our Texas corporate legal counsel is:

David Morris, Esq.
The Morris Law Firm
Dallas, Texas

Our securities legal counsel is:

The Lebrecht Group
Brian Lebrecht, Esq.
S. Jordan, Utah

7. Accountant or Auditor;

Our independent certified public accountant is Michael Morris, CPA. His telephone number is 702-253-7511 in Las Vegas, NV.

8. Public Relations Consultant.

None at this time.

B. Legal/Disciplinary History

To the best of our knowledge, none of the foregoing persons has, during the last five years, been the subject of the following except as follows:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the SEC, the CFTC, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated;

No.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended or otherwise limited such person's involvement in any type of business or securities activities.

No.

C. Beneficial Owners

The following table sets forth, as of June 30, 2008, certain information with respect to the Company's equity securities owned on record or beneficially by (i) each Officer and Director of the Company; (ii) each person who owns beneficially more than five percent (5%) of each class of the Company's outstanding equity securities; and (iii) all Directors and Executive Officers as a group.

Common Stock	Title of Class	Name and Address of Beneficial Owner (1)	Amount and Nature of Beneficial Ownership Percent of Class (2)
Common Stock		BioTech Medics Trust Keith A. Houser, Trustee	Shares 50.3%
Common Stock		BioTech Medics Trust Charles R. Crane, Trustee	10.7%
Common Stock		BioTech Medics Trust	5.0%
Executive Officers and Directors as a Group		(3 Persons)	66.0%

(1) Unless otherwise noted, the address of each beneficial owner is in c/o The Company.

(2) As of June 30, 2008, each of the Officers and Directors above have common stock that is subject to options or warrants currently exercisable, or exercisable under Employment Agreements, are deemed outstanding for purposes of computing the percentage of the person holding such options or warrants, but are not deemed outstanding for purposes of computing the percentage of any other person.

D. Disclosure of Certain Relationships

The Company has entered into a few third-party leases, loans, and/or credit card facilities. As a requirement of the various lease, loan and/or credit card facilities, Keith Houser has had to personally guarantee these leases, loans, and/or credit card facilities. The Company has agreed to indemnify Mr. Houser for any and all expenses and/or obligations for his personally guaranteeing these matters.

The Company has proffered leases being available for customers of medical laser products. A Delaware lease company has assumed a lease from a third party Washington State lease company and offered the equipment to the Santa Fe affiliated pain center. Mr. Houser is an officer and director of the Delaware lease company. Mr. Houser was a director of the Delaware company prior to his becoming an officer and director of BioTech Medics, Inc.

Item 12. Issuer's Most Recent Balance Sheet and Profit and Loss and Retained Earnings Statements:

Our unaudited financial statements as of the second quarter ending, June 30, 2008, are enclosed herewith. Our CPA has not completed review of these statements.

Item 13. Similar Financial Information for Such Part of the Two Preceding Fiscal Years as the Issuer or its Predecessor Has Been in Existence:

Our unaudited financial statements as of the end of the last two fiscal years ended December 31, 2006, and 2007, are enclosed herewith.

Item 14. Whether Quotation is Being Submitted or Published Directly or Indirectly on Behalf of Issuer, or any Director, Officer, or any Person, Directly or Indirectly the Beneficial Owner of More Than Ten Percent (10%) of the Outstanding Shares of the Issuer's Equity Securities, and, if so, the Name of Such Person, and Basis for any Exemption under the Federal Securities Laws for any Sale of Such Securities on Behalf of Such Person:

There is no existing market for our common stock. We do not know if one will develop and possibly impede your ability to sell your shares and depress our stock price. There has not been a public market for our common stock prior to this offering. We cannot predict the extent to which a trading market will develop or how liquid that market might become. If you purchase shares of common stock in this Company, you may pay a price

that was not established in the public trading markets as our trades are “unsolicited orders”. This may change in the future.

To the best of management’s knowledge, no quotations are being submitted by any broker or dealer on behalf of the Issuer. The Company is a non-reporting entity and has not contracted with any broker or securities dealer to represent BioTech.

All information contained herein is subject to change, modification and/or revision without notice. However, issuer will notify Pinksheets of any material changes.

Special Note Regarding Forward-Looking Information

This Form 211 includes forward-looking statements. These statements relate to forecasts of future prospects, business strategies and operating results and estimates. The statements contained in this form that are not statements of historical fact may include forward-looking statements that involve a number of risks and uncertainties. Some of these statements can be identified by the use of forward-looking terminology such as “believes,” “expects,” “estimates,” “intends,” “may,” “will,” “should,” or “anticipates,” or the negatives or other variations of these or similar words, or by discussion of strategies or risks and uncertainties. In addition, from time to time we or our representatives have made or may make forward-looking statements orally or in writing. Furthermore, such forward-looking statements may be included in various filings that we make with governmental authorities, or press releases or oral statements made by or with the approval of one of our authorized executive officers.

We undertake no obligations to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained in this form.

DISCLAIMERS

An investment in our stock is speculative, involves a high degree of risk, and should be considered only by sophisticated investors who can bear the economic risks of their investment for an indefinite period and who can afford to sustain a total loss of their investment.

The publishing of this document at any subsequent date to the 30th day of June, 2008 should not create any implication that there has been no change in the information set forth herein or in the financial condition or prospects of BioTech Medics, Inc.

An investor is responsible for making your own examination of us and your own assessment of the merits and risks of investing in shares of BioTech’s common stock.

We are not providing you with any legal, business, tax or other advice in this Form 211. You should consult with your own advisors as needed to assist you in making your investment decision and to advise you whether you are legally permitted and financially able to purchase the shares.

Dated this 30th day of June, 2008

BIOTECH MEDICS, INC.

s/ Keith A. Houser

By: Keith A. Houser
Its: Chief Executive Officer